Case Report: Severe kidney involvement in a case of very early onset inflammatory bowel disease

BackgroundPatients affected by very early onset inflammatory bowel disease (VEO-IBD) are frequently refractory to standard treatments. Despite the lack of randomized clinical trials, vedolizumab emerged as an effective and safe alternative treatment in VEO-IBD resistant to TNF antagonists. Here, we...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Enrico Drago, Roberta Carfora, Barbara Cafferata, Gabriele Gaggero, Laura Puzone, Edoardo La Porta, Sara Signa, Paolo Gandullia, Valerio Gaetano Vellone, Andrea Angeletti, Serena Arrigo
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2025-11-01
Rangatū:	Frontiers in Immunology
Ngā marau:	VEO-IBD vedolizumab ulcerative colitis tubulointerstitial nephritis (TIN) drug-induced acute interstitial nephritis
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1684476/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Case Report: Severe kidney involvement in a case of very early onset inflammatory bowel disease

Ngā tūemi rite